NWAM LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

NWAM LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$224K	Sell	906 -6	-0.7%	-$1.53K	0.01%	653
2026 Q2	$275K	Sell	912 -2	-0.2%	-$603	0.01%	585
2026 Q1	$302K	Hold	914	–	–	0.02%	500
2025 Q4	$330K	Buy	914 +2	+0.2%	+$885	0.02%	482
2025 Q3	$448K	Hold	912	–	–	0.02%	436
2025 Q2	$358K	Buy	912 +5	+0.6%	+$1.38K	0.02%	471
2025 Q1	$245K	Buy	907 +1	+0.1%	+$257	0.02%	448
2024 Q4	$213K	Buy	906 +50	+6%	+$13.2K	0.01%	559
2024 Q3	$235K	Buy	856 +4	+0.5%	+$1.04K	0.01%	552
2024 Q2	$207K	Buy	+852	New	+$135K	0.06%	142
2023 Q1	–	Sell	-850	Closed	-$202K	–	481
2022 Q4	$202K	Buy	+850	New	+$181K	0.02%	493

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

NWAM LLC's ALNY Position: Q3 2026 in Review

NWAM LLC reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.66% in Q3 2026, selling an estimated $1.53K and leaving 906 shares worth $224K. The position accounts for 0.01% of the portfolio, ranked #653.

NWAM LLC first reported a position in ALNY in Q4 2022 and has held it in 11 quarters since. The position peaked at $448K in Q3 2025. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

NWAM LLC held 906 shares of Alnylam Pharmaceuticals worth $224K as of Q3 2026.
NWAM LLC sold 6 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.53K.
Alnylam Pharmaceuticals made up 0.01% of NWAM LLC's portfolio in Q3 2026, its #653 holding.
NWAM LLC first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
NWAM LLC's Alnylam Pharmaceuticals position peaked at $448K in Q3 2025.
591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on NWAM LLC's 13F filing for Q3 2026, filed 9 Nov 2026.